10 years Biotalys

– Biotalys was founded as a spin-o from the VIB and was hosted in the Ghent VIB Biotechnology Incubator

– Series A financing (EUR

5 million) to which, among others, Gimv NV, PMV NV, VIB, Agri Investment Fund

CVBA, Biovest NV, Madeli Participaties B.V. and Qbic participated

– Start BioFun-1 project, leading to the development of Biotalys’ first biofungicide Evoca™

– Series B financing (EUR

11 million) adding K&E BV and Sofinnova Partners

“Originally, we wanted to use antibodies to develop new formulations to improve the performance of existing crop protection products. Besides this main activity, we also had a ‘Friday afternoon’ project, where we selected antibodies that would not only adhere to a fungus, but would also kill fungi. And so it happened, which ultimately led to a key focus area of Biotalys today.”

— Marnix Peferoen - Founder and former CEO of Biotalys

– Start of extensive field trial programs in the U.S., EU, Japan and South Africa to develop its first product Evoca

– Series C financing (EUR

45.1 million) adding Ackermans & van Haaren NV and Novalis

LifeSciences

– Biotalys demonstrated with its CMO partner the ability to scale up the production of AGROBODY™ proteins to 35,000 L

– Biotalys incorporated its U.S. subsidiary Biotalys, Inc. to prepare for the market entry of Evoca, to support the product development activities and to establish business and corporate relationships

“We believe that Biotalys’ strong underlying technology can provide an effective solution to the major challenges within the agricultural sector. For Agri Investment Fund, the investment in Biotalys has great added value for its own goals: to contribute to a stronger and more reliable agriculture with a view to a reliable income for the farmer.”

— Patrik Haesen - CEO Agri Investment Fund